Jazz Pharmaceuticals (JAZZ)
(Real Time Quote from BATS)
$136.15 USD
+1.90 (1.42%)
Updated Oct 17, 2025 03:36 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/05/2025
Time: -- |
9/2025 | $5.85 | -3.90% |
Earnings Summary
For their last quarter, Jazz Pharmaceuticals (JAZZ) reported earnings of -$8.25 per share, missing the Zacks Consensus Estimate of -$6.12 per share. This reflects a negative earnings surprise of 34.80%. Look out for JAZZ's next earnings release expected on November 05, 2025. For the next earning release, we expect the company to report earnings of $5.85 per share, reflecting a year-over-year decrease of 11.5%.
Earnings History
Price & Consensus
Zacks News for JAZZ
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why JAZZ Stock Is an Unconventional Cannabis Investment
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
JAZZ FAQs
Based on past history, Zacks believes Jazz Pharmaceuticals PLC (JAZZ) will report their next quarter earnings on November 05, 2025. For the next earning release, we expect the company to report earnings of 5.85 per share, reflecting a year-over-year increase of -11.50.
Based on past history, Zacks believes Jazz Pharmaceuticals PLC (JAZZ) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 05, 2025.
The Zacks Consensus Estimate for Jazz Pharmaceuticals PLC (JAZZ) for the quarter ending in September 2025 is $5.85 a share. We expect Jazz Pharmaceuticals PLC to miss by -3.90%.
In the earnings report for the quarter ending in June 2024, Jazz Pharmaceuticals PLC (JAZZ) announced earnings of $5.30 per share versus the Zacks Consensus Estimate of $4.68 per share, representing a surprise of 13.25%.